share_log

Enlivex Announces Interim Efficacy Data From Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis; The Interim Efficacy Results Are Statistically Significant, And Show Marked Improvements In All Key Efficacy Endpoints, Including...

Enlivex Announces Interim Efficacy Data From Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis; The Interim Efficacy Results Are Statistically Significant, And Show Marked Improvements In All Key Efficacy Endpoints, Including...

Enlivex宣佈分配試驗中的中期療效數據,適用於中度至重度膝關節骨關節炎患者;中期療效結果具有統計學意義,並顯示所有關鍵療效終點包括明顯改善...
Benzinga ·  12/03 21:32

Enlivex Announces Interim Efficacy Data From Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis; The Interim Efficacy Results Are Statistically Significant, And Show Marked Improvements In All Key Efficacy Endpoints, Including Reduction Of Pain And An Improvement In Functionality, Compared To Baseline

enlivex宣佈對中重度膝關節骨關節炎患者進行Allocetra試驗的中期療效數據;中期療效結果具有統計學意義,顯示在所有關鍵療效終點上都有顯著改善,包括減輕疼痛和功能性改善,與基線相比

Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II Allocetra trial in patients with moderate to severe knee osteoarthritis.

納斯達克上的enlivex therapeutics有限公司(NASDAQ:ENLV,《公司》),一家臨床階段的巨噬細胞重編程免疫療法公司,今天宣佈了在中重度膝關節骨關節炎患者中進行的隨機、多國階段I/II Allocetra試驗的第I階段的積極中期療效數據。

The multi-center Phase I/II clinical trial consists of two stages. The first stage, which was successfully completed, was a Phase I safety run-in, open-label dose escalation phase to characterize the safety and tolerability of Allocetra injections to the target knee in order to identify the dose and injection regimen for the subsequent Phase II stage.

這項多中心I/II臨床試驗包括兩個階段。第一個階段已成功完成,是一個Phase I安全試運行、開放標籤劑量遞增階段,旨在表徵Allocetra注射物對目標膝蓋的安全性和耐受性,以確定後續Phase II階段的劑量和注射方案。

The Company previously announced that no serious adverse reactions were reported during or following treatment in the Phase I stage. The information below details the interim efficacy data with respect to the treatment of these patients, measured three months following the administration of Allocetra injections. The interim efficacy results are highly positive, statistically significant (p-value < 0.0007, n=12), and show marked improvements in all key efficacy endpoints, including reduction of pain and an improvement in functionality, compared to baseline.

該公司此前宣佈,在Phase I階段治療過程中或治療後未報告任何嚴重不良反應。以下信息詳細說明了關於這些患者治療情況的中期療效數據,這些數據是在給予Allocetra注射物後三個月測量的。中期療效結果非常積極,具有統計學意義(p值

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論